Categories: News

ViCentra to Participate at the upcoming MedTech Strategist Innovation Summit and LSX London Conference

UTRECHT, The Netherlands, April 12, 2023 (GLOBE NEWSWIRE) — ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most precise Insulin Pump systems for treating people with Diabetes, today announced that management will present a corporate overview at the following conferences in April and May. Please see details below:

MedTech Strategist Innovation Summit, Dublin, Ireland

Title:  ViCentra Company Presentation
Date:  Tuesday, April 25th, 2023
Time: 16:40 local time
Presenter: Frans Cromme, CEO
   

LSX World Congress, London, UK

Title:  ViCentra Company Presentation
Date: Wednesday, May 3rd, 2023
Time: 14:45 local time  
Presenter: Frans Cromme, CEO
   

If you are interested in arranging a one-on-one meeting request, please contact your conference representative or Leo Toole at ViCentra.

About ViCentra B.V.
ViCentra, the company behind Kaleido is based in the Netherlands. Our philosophy is to make innovative products that put people first. With our focus on diabetes, we develop our products not for patients, but for people. We believe that when products are simple, are designed beautifully, and deliver outstanding results. They provide more user enjoyment and help people live better on their own terms. It was with this philosophy in mind that Kaleido was born. Kaleido is a pioneering insulin delivery system for people with type 1 diabetes. Through its unique pulse technology, it provides extremely precise and reliable delivery of insulin, giving its user the peace of mind and freedom that’s often missing for those with a long term health condition. To learn more about ViCentra, visit the Company’s website at https://hellokaleido.com/.

Company Contacts:
Frans Cromme, CEO
frans.cromme@vicentra.com

Leo Toole, CFO
leo.toole@vicentra.com  
Investor Relations Contact:
Michael Wood
LifeSci Advisors
mwood@lifesciadvisors.com

 

Staff

Recent Posts

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United…

52 mins ago

Universal Recall Platform Alliance Launches to Keep Patients Safe

Industry initiative URPA broadens calls to improve speed, accuracy of recall communicationWEST HOLLYWOOD, CA /…

52 mins ago

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

4 hours ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

4 hours ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

4 hours ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

4 hours ago